Assessing the Opportunities and Challenges in the Oncology Segment

Oncology is the study of cancer and encompasses the diagnosis and treatment of cancer. The treatment of cancer requires a multidisciplinary approach which includes medications, surgical, and radiation. The type of approach adopted depends upon the stages, age, and the patient’s preference.

Cancer encompasses a group of diseases, which can affect any organ or tissue of the body. In men, Lung, prostate, colorectal, stomach, and liver cancer are the most common types of cancer while in females the breast, colorectal, lung, cervical, and thyroid cancer are the most common. As per the World Health Organization (WHO), 9.6 million people worldwide are estimated to have died from cancer in 2018. The growing burden of cancer is causing significant physical, emotional, and financial strain on the affected person. The estimated total annual economic cost of cancer in 2010 was US$ 1.16 trillion.

Oncology is one of the most competitive healthcare domains as several key players at the global level are involved in R&D activities to provide an effective therapeutic option for the people affected with different cancer.  Over the past few years, the global oncology market has observed significant growth owing to various factors such as the rise in research and development activities, increasing awareness, the surge in geriatric population, rise in the incidence of various cancer conditions, and growing interest of the key pharmaceutical and biotech companies in the domain. Similarly, the rise in various government and non-government initiatives to curb the occurrence of cancer diseases and the availability of cancer therapies has also contributed immensely to market growth. However, regulatory changes, high cost in new drug development, and adverse effects of the therapies are the key factors hampering the Oncology market growth.

DelveInsight offers a wide range of Oncology Reports to formulating business strategies based on recent trends and development, challenges, opportunities that ultimately assist the companies in positioning the Oncology market against competitors.

Delveinsight’s Oncology Based Reports are classified as –

• Market Reports
• Epidemiology Reports
• Drug Insights Reports
• Cancer Diagnostics Reports 

Delveinsight’s Oncology Based Reports provides the latest developments in the Oncology segment. It covers the in-depth analysis of epidemiology as well as the emerging therapies in the market. Moreover, it provides an assessment of the market size, share, trends in the seven major markets (7MM) (i.e the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. The epidemiology-based Oncology report by Delveinsight offers an in-depth understanding of the disease, historical and forecasted epidemiology in the 7MM. It covers the total patient pool according to the incident cases, treated cases, diagnosed cases, and also according to the gender and age of the population. 

Similarly, Delveinsight’s Oncology Based Reports related to Drug Insights cover the major manufacturers that produce pharmaceutical drugs. The drug reports are classified as branded drugs and generic drugs. It provides a comprehensive analysis into the mechanism of action, dosage and administration, route of synthesis, and research and development activity including regulatory milestones, and other development activities. The Diagnostics Reports cover an in-depth analysis of the historical and forecasted market trends for the diagnostic device including applications, market share, market drivers, market barriers, unmet needs, key companies operating in the market, and pipeline products.

Currently, several global pharmaceutical companies are operating in the Oncology therapeutics segment. In the coming years, with the entry of new players in the domain, the development of innovative drugs, and advancement in diagnostics devices are expected to improve the quality of life of the affected person and their families.